# AtriCure, Inc.: overview

ATRC · Nasdaq · CIK 1323885 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/atrc.md) · [Financials](/companies/atrc/financials.md) · [Filings](/companies/atrc/filings.md) · [Insiders](/companies/atrc/insiders.md)

Latest reported revenue: [$153.6m](/filings/0001323885-26-000035.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 27, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001323885-26-000035).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [116](/filings/0001323885-25-000103.md) | [124 d](/filings/0001323885-26-000007.md) | [124](/filings/0001323885-26-000023.md) | [136](/filings/0001323885-26-000035.md) | [134](/filings/0001323885-25-000103.md) | [141 d](/filings/0001323885-26-000007.md) | [141](/filings/0001323885-26-000023.md) | [154](/filings/0001323885-26-000035.md) |
| Gross margin | % | [74.9%](/filings/0001323885-25-000103.md) | [74.5% d](/filings/0001323885-26-000007.md) | [74.9%](/filings/0001323885-26-000023.md) | [74.5%](/filings/0001323885-26-000035.md) | [75.5%](/filings/0001323885-25-000103.md) | [75.0% d](/filings/0001323885-26-000007.md) | [77.4%](/filings/0001323885-26-000023.md) | [77.2%](/filings/0001323885-26-000035.md) |
| Operating margin | % | [(6.4%)](/filings/0001323885-25-000103.md) | [(11.7%) d](/filings/0001323885-26-000007.md) | [(4.8%)](/filings/0001323885-26-000023.md) | [(4.5%)](/filings/0001323885-26-000035.md) | [0.2%](/filings/0001323885-25-000103.md) | [1.8% d](/filings/0001323885-26-000007.md) | [0.4%](/filings/0001323885-26-000023.md) | [6.3%](/filings/0001323885-26-000035.md) |
| Net margin | % | [(6.8%)](/filings/0001323885-25-000103.md) | [(12.5%) d](/filings/0001323885-26-000007.md) | [(5.5%)](/filings/0001323885-26-000023.md) | [(4.5%)](/filings/0001323885-26-000035.md) | [(0.2%)](/filings/0001323885-25-000103.md) | [1.2% d](/filings/0001323885-26-000007.md) | [0.1%](/filings/0001323885-26-000023.md) | [5.8%](/filings/0001323885-26-000035.md) |
| Diluted EPS | $ per share | [(0.17)](/filings/0001323885-25-000103.md) | not reported | [(0.14)](/filings/0001323885-26-000023.md) | [(0.13)](/filings/0001323885-26-000035.md) | [(0.01)](/filings/0001323885-25-000103.md) | not reported | [0.00](/filings/0001323885-26-000023.md) | [0.18](/filings/0001323885-26-000035.md) |
| Free cash flow | $m | [16.4 d](/filings/0001323885-25-000103.md) | [3.1 d](/filings/0001323885-26-000007.md) | [(13.2)](/filings/0001323885-26-000023.md) | [19.0 d](/filings/0001323885-26-000035.md) | [24.1 d](/filings/0001323885-25-000103.md) | [18.4 d](/filings/0001323885-26-000007.md) | [(7.8)](/filings/0001323885-26-000023.md) | [18.4 d](/filings/0001323885-26-000035.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [274](/filings/0001323885-24-000016.md) | [330](/filings/0001323885-25-000009.md) | [399](/filings/0001323885-26-000007.md) | [465](/filings/0001323885-26-000007.md) | [535](/filings/0001323885-26-000007.md) |
| Gross margin | % | [75.0%](/filings/0001323885-24-000016.md) | [74.4%](/filings/0001323885-25-000009.md) | [75.2%](/filings/0001323885-26-000007.md) | [74.7%](/filings/0001323885-26-000007.md) | [75.0%](/filings/0001323885-26-000007.md) |
| Operating margin | % | [20.1%](/filings/0001323885-24-000016.md) | [(12.9%)](/filings/0001323885-25-000009.md) | [(6.7%)](/filings/0001323885-26-000007.md) | [(8.6%)](/filings/0001323885-26-000007.md) | [(1.8%)](/filings/0001323885-26-000007.md) |
| Net margin | % | [18.3%](/filings/0001323885-24-000016.md) | [(14.1%)](/filings/0001323885-25-000009.md) | [(7.6%)](/filings/0001323885-26-000007.md) | [(9.6%)](/filings/0001323885-26-000007.md) | [(2.1%)](/filings/0001323885-26-000007.md) |
| Diluted EPS | $ per share | [1.09](/filings/0001323885-24-000016.md) | [(1.02)](/filings/0001323885-25-000009.md) | [(0.66)](/filings/0001323885-26-000007.md) | [(0.95)](/filings/0001323885-26-000007.md) | [(0.24)](/filings/0001323885-26-000007.md) |
| Free cash flow | $m | [(23.5)](/filings/0001323885-24-000016.md) | [(39.0)](/filings/0001323885-25-000009.md) | [(7.5)](/filings/0001323885-26-000007.md) | [0.7](/filings/0001323885-26-000007.md) | [48.3](/filings/0001323885-26-000007.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/atrc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $125.2m | 4,474,548 |  | Added +431,867 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $97.8m | 3,495,603 |  | Added +113,048 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $87.5m | 3,127,195 |  | Added +424,563 |
| [Hood River Capital Management LLC](/funds/1578177.md) | 2026-06-30 | $81.3m | 2,905,299 |  | Reduced −212,246 |
| [ALLIANCEBERNSTEIN L.P.](/funds/1109448.md) | 2026-06-30 | $79.0m | 2,768,365 |  | Reduced −490,507 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $61.3m | 2,190,413 |  | Added +34,649 |
| [NOMURA ASSET MANAGEMENT INTERNATIONAL INC.](/funds/921739.md) | 2026-06-30 | $48.5m | 1,734,279 |  | Reduced −70,648 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $44.7m | 1,597,988 |  | Reduced −69,178 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $38.9m | 1,389,989 |  | Added +87,827 |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $37.3m | 1,333,904 |  | Reduced −133,620 |

## Recent filings

[All 1,326 filings](/companies/atrc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-07-27 | 13:07 ET | [10-Q](/filings/0001323885-26-000035.md) | Quarterly report, period 2026-06-30 | 0001323885-26-000035 |
| 2026-07-23 | 16:00 ET | [8-K](/filings/0001323885-26-000032.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001323885-26-000032 |
| 2026-05-19 | 16:21 ET | [8-K](/filings/0001323885-26-000025.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001323885-26-000025 |
| 2026-05-06 | 12:31 ET | [10-Q](/filings/0001323885-26-000023.md) | Quarterly report, period 2026-03-31 | 0001323885-26-000023 |
| 2026-05-06 | 21:01 ET | [8-K/A](/filings/0001323885-26-000020.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001323885-26-000020 |
| 2026-05-05 | 16:00 ET | [8-K](/filings/0001323885-26-000018.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001323885-26-000018 |
| 2026-04-06 | 11:54 ET | [DEF 14A](/filings/0001323885-26-000010.md) | Proxy statement, period 2026-04-06 | 0001323885-26-000010 |
| 2026-02-19 | 12:39 ET | [10-K](/filings/0001323885-26-000007.md) | Annual report, period 2025-12-31 | 0001323885-26-000007 |
| 2026-02-17 | 16:00 ET | [8-K](/filings/0001323885-26-000005.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001323885-26-000005 |
| 2026-01-12 | 08:00 ET | [8-K](/filings/0001193125-26-009814.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-009814 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001323885-26-000007.md), filed Feb 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/74b9817e-de9a-4b70-89c5-07cc6205bb42)

## About the filer

- CIK: 1323885
- Tickers: ATRC
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 13:40 ET. No prices; not investment advice.